^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Nanoplatin (demplatin pegraglumer)

    i
    Other names: NC-6004, NC 6004
    Associations

    News

    Trials
    Company:
    NANO MRNA, Orient Europharma
    Drug class:
    DNA cross linking agent
    Related drugs:
    Associations

    News

    Trials
    3ms
    Combination Therapy With NC-6004 and Gemcitabine in Advanced Solid Tumors or Non-Small Cell Lung, Biliary and Bladder Cancer (clinicaltrials.gov)
    P1/2, N=119, Completed, NanoCarrier Co., Ltd. | Phase classification: P1b/2 --> P1/2 | N=209 --> 119
    Phase classification • Enrollment change • Combination therapy • Metastases
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    gemcitabine • Nanoplatin (demplatin pegraglumer)
    over4years
    Combination Therapy With NC-6004 and Gemcitabine in Advanced Solid Tumors or Non-Small Cell Lung, Biliary and Bladder Cancer (clinicaltrials.gov)
    P1b/2, N=209, Completed, NanoCarrier Co., Ltd. | Active, not recruiting --> Completed | Trial completion date: Nov 2019 --> May 2019 | Trial primary completion date: Nov 2019 --> May 2019
    Clinical • Trial completion • Trial completion date • Trial primary completion date • Combination therapy
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation • ALK fusion
    |
    gemcitabine • Nanoplatin (demplatin pegraglumer)